Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Inmune Bio, Inc. (INMB)

INmune Bio prices $4.5 million registered direct offering and private warrant sale

Negative Impact 3 of 5 financing Written later

INmune Bio agreed to sell 3,000,000 shares at $1.50 each in a registered direct offering to a single investor, with gross proceeds expected to be about $4.5 million before placement agent fees and expenses. The company also issued unregistered warrants for up to 3,000,000 shares at $1.65 per share, so the deal adds potential dilution for existing shareholders. The company said it intends to use the net proceeds for working capital and general corporate purposes.

Key points

  • 3,000,000 common shares sold at $1.50 per share, with gross proceeds of about $4.5 million expected before fees
  • Unregistered warrants for up to 3,000,000 shares at $1.65 per share, first exercisable April 27, 2027 and expiring April 27, 2032
  • Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
  • Closing expected on or about October 29, 2026, subject to customary conditions

The filing

CompanyInmune Bio, Inc. (INMB)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:40 AM ET
Accession number0001213900-26-113535

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.